Anjali Babbar

Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities

Diversity oriented clicking delivers β-substituted alkenyl sulfonyl fluorides as covalent human neutrophil elastase inhibitors

Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution

The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2

Exploring Targeted Degradation Strategy for Oncogenic KRASG12C

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

mTOR at the nexus of nutrition, growth, ageing and disease

RAS-targeted therapies: is the undruggable drugged?

Therapeutic strategies to target RAS-mutant cancers

Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Broadening horizons: the role of ferroptosis in cancer

Regulation and Function of the PD-L1 Checkpoint

PROTAC targeted protein degraders: the past is prologue

Applications of machine learning in drug discovery and development

The current understanding of KRAS protein structure and dynamics

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

Proteome-wide covalent ligand discovery in native biological systems

Protein Ensemble Generation Through Variational Autoencoder Latent Space Sampling

“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors